Nasopharyngeal Cancer

Nasopharyngeal cancer (NPC) is a type of head and neck cancer that originates from the upper part of the throat behind the nose. Its characteristics are associated with Epstein-Barr virus (EBV) infection and have unique epidemiological characteristics. Alfa Cytology is a world leader in head and neck cancer. and can provide the best solutions for NPC.

Introduction to Nasopharyngeal Cancer

The main cause of nasopharyngeal cancer is believed to be a combination of genetic susceptibility and environmental factors, especially EBV infection. The incidence rate is high in some geographical regions, including Southeast Asia, North Africa, and the Arctic. There are three main histological types of nasopharyngeal cancer.

Non-Keratinizing Carcinoma

This is the most common histological subtype of nasopharyngeal carcinoma, divided into differentiated and undifferentiated types.

Keratinizing Squamous Cell Carcinoma

This subtype is less common and more similar to other squamous cell carcinoma found in other parts of the head and neck.

Undifferentiated Carcinoma with Lymphoid Stroma

This subtype is rare and characterized by abundant lymphatic infiltration within the tumor.

Therapy for Nasopharyngeal Cancer

The therapy of nasopharyngeal cancer typically involves a multimodal approach, combining different modalities based on the stage and extent of the disease. Novel therapy options include the following.

Targeted therapy: EGFR inhibitors, such as cetuximab, have shown potential in combination with radiotherapy for locally advanced nasopharyngeal cancer. Trials are currently investigating new targeted therapies that may further improve therapy outcomes.
Immunotherapy: Checkpoint inhibitors targeting the PD-1/PD-L1 pathway, such as pembrolizumab, are effective in recurrent or metastatic NPC. The ongoing research explores the immunotherapy application in different stages of nasopharyngeal cancer.

Chemotherapy is prone to drug resistance. Fig.1 Chemotherapy resistance is a major obstacle to recurrent nasopharyngeal carcinoma. (Guan, S., et al., 2020)

Our Services

Alfa Cytology works on developing more effective and personalized therapy methods to improve this challenging disease situation. We provide one-stop solutions for nasopharyngeal cancer, including but not limited to the following.

Cancer Diagnostic Development

Cancer Modeling Services

Preclinical Research Services

Models of Nasopharyngeal Cancer

Animal models play a crucial role in nasopharyngeal cancer research to understand the pathogenesis of the disease, evaluate potential therapies, and explore drug action mechanisms. Research on tumor growth can test potential therapies.

Types of Model	Optional Species
3D Tumor Modeling	Mice
Xenograft Model	Rats
Immuno-Oncology Tumor Models	Non-human Primates

Alfa Cytology is committed to the research and study of cancer, from therapeutic antibody development services, and cancer vaccine development services, to cancer modeling services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for nasopharyngeal cancer. If you are interested in our service, please contact us for more details.

Reference

Guan, S., et al.; (2020). Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. European Journal of Medicinal Chemistry, 207, 112758.

For research use only.